What is RedDress?
Founded in 2009, RedDress operates at the intersection of biotechnology and clinical wound management. The company is primarily recognized for its innovative ActiGraft system, a point-of-care solution that utilizes a patient's own blood to create a natural, autologous wound healing matrix. This approach addresses the critical need for more effective and economically sustainable treatments for chronic wounds, a condition that affects millions of patients globally. With a dual presence in Israel and the United States, specifically in Ponte Vedra Beach, Florida, RedDress maintains a strategic bridge between high-level research and development and the expansive North American healthcare market. The company's commitment to improving patient outcomes through natural, regenerative medicine has established it as a significant player in the wound care sector, distinguishing its offerings from traditional synthetic or pharmacological alternatives.
How much funding has RedDress raised?
RedDress has raised a total of $26M across 1 funding round:
Series D
$26M
Series D (2023): $26M with participation from HCS Capital Partners
Key Investors in RedDress
HCS Capital Partners
A Miami-based venture capital firm that partners with technology-driven companies across Latin America, North America, and Israel, specializing in technology strategy, globalization, and operational scaling.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for RedDress?
With the successful closure of this major strategic investment, RedDress is poised to enter a new phase of organizational scaling and market expansion. The company is expected to prioritize the clinical adoption of ActiGraft, focusing on increasing its presence in major hospital systems and specialized wound care centers. Furthermore, the capital will likely support ongoing research initiatives aimed at broadening the application of its regenerative technology. As the firm navigates the complexities of the global medical device market, the focus will remain on operational excellence and the continued validation of its clinical efficacy. By strengthening its strategic partnerships and optimizing its supply chain, RedDress is set to solidify its leadership position in the regenerative medicine space, ultimately aiming to improve the quality of life for patients suffering from complex, non-healing wounds.
See full RedDress company page
